The biological properties of cancer stem cells in malignant gliomas in tissue culture: a review

Cell and Organ Transplantology. 2015; 3(2):163-168.
DOI: 10.22494/COT.V3I2.12

The biological properties of cancer stem cells in malignant gliomas in tissue culture: a review

Semenova V. M., Lisyany M. I., Rosumenko V. D., Egorova D. M., Staino L. P.
A. P. Romodanov State Institute of Neurosurgery NAMS of Ukraine, Kyiv, Ukraine

Abstract
This review presents recent data on the biological properties of cancer stem cells in brain gliomas. The possibilities of using of experimental methods of cell culture and immunohistochemical identification of tumor stem cells as a part of neurospheres (tumorospheres) are shown. Methodological features of neurospheres culture are described.
Literature data about the dependence of neurospheres formation activity in the culture on the degree of anaplasia of original glioma tissues are presented considering the disease outcomes in neuro-oncological patients. Possibilities of the practical use of cultured tumorospheres in the study of selective impact of antiblastic drugs on tumor stem cells in gliomas are described.

Key words: cancer stem cells, glioma, cell culture, neurosphere

Full Text PDF (eng) Full Text PDF (ru)

References

1. Gursel DB, Shin BJ, Burkhardt J-K, et. al. Glioblastoma Stem-Like Cells – Biology and Therapeutic Implications. Cancers. 2011; 3(2):2655–2666. https://doi.org/10.3390/cancers3022655 PMid:21796273 PMCid:PMC3142771

2. Park DM. Biology of Glioma Cancer Stem Cells. Mol. Cells. 2009; 28:7–12. https://doi.org/10.1007/s10059-009-0111-2 PMid:19655094

3. Lisyany NI. Immunologija i immunoterapija zlokachestvennyh gliom golovnogo mozga. [Immunology and Immunotherapy of malignant gliomas of the brain]. Serija “Nejroimmunologija” Kiev: Interservis – Series “Neuroimmunology”. Kiev: Interservice. 2011; 5:240 p.

4. Wang JC. Evaluating Therapeutic efficacy against cancer stem cells: New challenges posed by a new paradigm. Cell Stem Cell. 2007; 1:497–501. https://doi.org/10.1016/j.stem.2007.10.005 PMid:18938746

5. Bleau AM, Howard BM, Taylor LA, et al. New strategy for the analysis of phenotypic marker antigens in brain tumor-derived neurospheres in mice and humans Neurosurg. Focus. 2008; 24(3-4):E 28.

6. Pollard SM, Yoshikawa K, Clarke ID, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009; 4:568–580. https://doi.org/10.1016/j.stem.2009.03.014 PMid:19497285

7. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. Engl. J. Med. 2005; 353:811–822. https://doi.org/10.1056/NEJMra043666 PMid:16120861

8. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006; 9:391–403. https://doi.org/10.1016/j.ccr.2006.03.030 PMid:16697959

9. Kong BH, Park N-R, Shim J-K, et al. Isolation of glioma cancer stem cells in relation to histological grades in glioma specimens. Child’s Nervous System. 2013; 29(2):217–229. https://doi.org/10.1007/s00381-012-1964-9 PMid:23143002

10. Kok M, Koornstra RH, Margarido TC, et al. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer. The Journal of Pathology. 2009; 218(3):316–326. https://doi.org/10.1002/path.2544 PMid:19353633

11. Kim HS, Yoo SY, Kim KT, et al. Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance. International Journal of Clinical and Experimental Pathology. 2012; 5(8):754–761. PMid:23071857 PMCid:PMC3466976

12. Pirozzi G, Tirino V, Camerlingo R, et al. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer. Oncology Reports. 2013; 29(5):1763–1768. https://doi.org/10.3892/or.2013.2294

13. Bao B, Ali S, Ahmad A, et al. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Stem Cells and Development. 2014; 23(16):1947–1958. https://doi.org/10.1089/scd.2013.0551 PMid:24734907

14. Wang X, Ren H, Zhao T, et al. Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection. Carcinogenesis. 2014; 35(10):2283–2290. https://doi.org/10.1093/carcin/bgu162 PMid:25086759

15. Reya T, Morrison SJ, Clarce MF, et al. Stem cells cancer and cancer stem cells. Nature. 2001; 414:105–111. https://doi.org/10.1038/35102167 PMid:11689955

16. Singh SK, Clarke ID, Terasaki M, et al. Identification of Cancer Stem Cell in Human Brain Tumors. Cancer Res. 2003; 63(18):5821–5828. PMid:14522905

17. Sulman E. Aldape K, Colman H. Brain tumor stem cells. Current Problems in Cancer. 2008; 32(3):124–142. https://doi.org/10.1016/j.currproblcancer.2008.02.004 PMid:18501775

18. Binello E, Qadeer ZA, Kothari HP, Emdad L, et al. Stemness of the CT-2A Immunocompetent Mouse Brain Tumor Model: Characterization In Vitro. J. Cancer. 2012; 3:166–174. https://doi.org/10.7150/jca.4149 PMid:22514559 PMCid:PMC3328782

19. Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer res. 1992; 52:5334–5341. PMid:1382841

20. Tohyama T, Lee VM, Rorke LB, et al. Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab. Invest. 1992; 66:303–313. PMid:1538585

21. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumor initiating cells. Nature. 2004; 432:396–401. https://doi.org/10.1038/nature03128 PMid:15549107

22. Ben-Porath I, Thomson NW, Carev V J, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 2008; 40:499–507. https://doi.org/10.1038/ng.127 PMid:18443585 PMCid:PMC2912221

23. Mishima K, Kato Y, Kaneko MK, et al. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathologica. 2006; 111(5):483–488. https://doi.org/10.1007/s00401-006-0063-y PMid:16596424

24. Laks DR, Masterman-Smith M, Visnyei K, et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells. 2009; 27(4):980–987. https://doi.org/10.1002/stem.15 PMid:19353526 PMCid:PMC3177534

25. Dahlrot RH, Hermansen SK, Hansen S, et al. What is the clinical value of cancer stem cell markers in gliomas? International Journal of Clinical and Experimental Pathology. 2013; 6(3):334–348. PMid:23412423 PMCid:PMC3563206

26. Christensen K, Schrøder HD, Kristensen BW. CD133 identifies perivascular niches in grade II-IV astrocytomas. Journal of Neuro-Oncology. 2008; 90(2):157–170. https://doi.org/10.1007/s11060-008-9648-8 PMid:18612800

27. Kim K-J, Lee K-H, Kim H-S, et al. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology. 2011; 31(5):494–502. https://doi.org/10.1111/j.1440-1789.2010.01194.x PMid:21269333

28. Schoppmann SF, Berghoff AS, Jesch B, et al. Expression of podoplanin is a rare event in sporadic gastrointestinal stromal tumors and does not influence prognosis. Future Oncology. 2012; 8(7):859–866. https://doi.org/10.2217/fon.12.71 PMid:22830405

29. Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J. Neurosci. 1992; 12:4565–4574. PMid:1432110

30. Singec I, Knoth R, Meyer RP, et al. Defining the actual sensitivity and specificity of the neurosphere assay in stem cell biology. Nat. Methods. 2006; 3:801–806. https://doi.org/10.1038/nmeth926 PMid:16990812

31. Hasselbach LA, Irtenkauf SM, Lemke NW, et al. Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry. J. Vis. Exp. 2014; 83(e51088):1–9. https://doi.org/10.3791/51088

32. Qiang L, Yang Y, Ma YJ, et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett. 2009; 279(1):13–21. https://doi.org/10.1016/j.canlet.2009.01.016 PMid:19232461

33. Gilbert CA, Ross AH. Cancer Stem cells: Cell Culture, Markers and Targets for New Therapies. J.Cell.Biochem. 2009; 108(5):1031–1038. https://doi.org/10.1002/jcb.22350 PMid:19760641 PMCid:PMC2909872

34. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad .Sci. USA. 2003; 100:15178–15183. https://doi.org/10.1073/pnas.2036535100 PMid:14645703 PMCid:PMC299944

35. Ahmed S. The culture of neural stem cells. J. Cell Biochem. 2009; 106:1–6. https://doi.org/10.1002/jcb.21972 PMid:19021147

36. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004; 64(19):7011–7021. https://doi.org/10.1158/0008-5472.CAN-04-1364 PMid:15466194

37. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat. Rev. Cancer. 2006; 6:425–436. https://doi.org/10.1038/nrc1889 PMid:16723989

38. deCarvalho AC, Nelson K, Lemke N, et al. Gliosarcoma Stem Cells Undergo Glial and Mesenchymal Differentiation In Vivo. Stem Cells. 2010; 28(2):181–190. PMid:19937755 PMCid:PMC2873790

39. Azari H, Millette S, Ansari S, et al. Isolation and expansion of human glioblastoma multiforme tumor cells using the neurosphere assay. J. Vis. Exp. 2011; 56(e3633):1–5. https://doi.org/10.3791/3633

40. Woolard K, Fine HA. Glioma stem cells: better flat than round. Cell Stem Cell. 2009; 4: 466–467. https://doi.org/10.1016/j.stem.2009.05.013 PMid:19497271

41. Facchino S, Abdouh M, Chatoo W, et al. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J.Neurosci. 2010; 28(30):1096–1111. https://doi.org/10.1523/jneurosci.1634-10.2010

42. Yi L, Zhou C, Wang B, et al. Implantation of GL261 neurospheres into C57/BL6 mice: a more reliable syngenic graft model for research on glioma-initiating cells. Int.J.Oncol. 2013; 43(2): 477–484. PMid:23708048

43. Pavon LF, Marti LC, Sibov TT, et al. In vitro analysis of neurospheres derived from glioblastoma primary culture: a novel methodology paradigm. Front.Neurol. 2014; 4:214–220. https://doi.org/10.3389/fneur.2013.00214 PMid:24432012 PMCid:PMC3883037

44. Li SC, Long TV, Ho HW, et al. Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall. Cancer Cell International. 2012; 12:41–60. https://doi.org/10.1186/1475-2867-12-41 PMid:22995409 PMCid:PMC3546918

45. Bao S, Wu Q, MCLendon DE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006a; 444:756–760. https://doi.org/10.1038/nature05236 PMid:17051156

46. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD1339(-) glioblastoma-derived cancer stem cell show differential growth characteristics and molecular profiles. Cancer Res. 2007; 67: 4010–4015. https://doi.org/10.1158/0008-5472.CAN-06-4180 PMid:17483311

47. Joo KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab. Invest. 2008; 88:808–815. https://doi.org/10.1038/labinvest.2008.57 PMid:18560366

48. Son MJ, Woolard K, Nam DH, et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem cell. 2009; 4:440–452. https://doi.org/10.1016/j.stem.2009.03.003 PMid:19427293

49. Clement V, Marino D, Cudalbu C, et al. Marker-independent identification of glioma-initiating cells. Nature Methods. 2010; 7:224–228. https://doi.org/10.1038/nmeth.1430 PMid:20173750

50. Ignatova TN, Kukekov VG, Laywell ED, et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002; 39(3):193–206. https://doi.org/10.1002/glia.10094 PMid:12203386

51. Yuan X, Curtin J, Xion Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004; 23:9392–9400. https://doi.org/10.1038/sj.onc.1208311 PMid:15558011

52. Germano IM, Swiss V, Casaccia P. Primary brain tumors, neural stem cells, and brain tumor cancer cells: Where is the link? Neuropharmacol. 2010; 58(6):903–910. https://doi.org/10.1016/j.neuropharm.2009.12.019 PMid:20045420 PMCid:PMC2839061

53. Strojnik T, Røsland GV, Sakariassen PO, et al. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surgical Neurology. 2007; 68(2):133–143. https://doi.org/10.1016/j.surneu.2006.10.050 PMid:17537489

54. Beier D, Rohrl S, Pillai DR, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 2008; 68:5706–5715. https://doi.org/10.1158/0008-5472.CAN-07-6878 PMid:18632623

55. Pallini R, Ricci-Vitiani L, Banna GL, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clinical Cancer Research. 2008; 14(24):8205–8212. https://doi.org/10.1158/1078-0432.CCR-08-0644 PMid:19088037

56. Zeppernick F, Ahmadi R, Campos B, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 2008; 14(1):123–129. https://doi.org/10.1158/1078-0432.CCR-07-0932 PMid:18172261

57. Zhang M, Song T, Yang L, et al. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res. 2008; 27: 85–92. https://doi.org/10.1186/1756-9966-27-85 PMid:19108713 PMCid:PMC2633002

58. Wang X, Ren H, Zhao T, et al. Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection. Carcinogenesis. 2014; 35(10):2283–2290. https://doi.org/10.1093/carcin/bgu162 PMid:25086759

59. Kong BH, Moon JH, Huh UM, et al. Prognostic Value of Glioma Cancer Stem Cell Isolation in Survival of Primary Glioblastoma Patients. Stem Cells International. 2014; Article ID 838950. 6 p.

60. S. Bao, Q. Wu, Z. Li, S. Sathornsumetee, H. Wang, R.E. McLendon, A.B. Hjelmeland, J.N. Rich Targeting cancer stem cells through L1CAM suppresses glioma grouth / // Cancer Res. – 2008. – Vol. 68. – P. 7043–6048.

61. Dietrich J, Imitola J, Kesari S. Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas . Nat.Clin.Pract. 2008; 5:393–404. https://doi.org/10.1038/ncponc1132 PMid:18521117

62. Bao S, Wu Q, Sathornsumetae S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer.Res. 2006b; 66:7843–7848. https://doi.org/10.1158/0008-5472.CAN-06-1010 PMid:16912155

63. Ernst A, Hofmann S, Ahmadi R, et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clinical Cancer Research. 2009; 15(21):6541–6550. https://doi.org/10.1158/1078-0432.CCR-09-0695 PMid:19861460

64. Strojnik T, Rosland GV, Sakariassen PO, et al. Neural stem cell markers, nestin and musashi proteins, in the progress of human glioma: correlation of nestin with prognosis of parient survival. Surg Neurol. 2007; 68(2):133–144. https://doi.org/10.1016/j.surneu.2006.10.050 PMid:17537489

65. Pallini R, Ricci-Vitiani L, Banna GL, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res. 2008; 14(24):8205–8212. https://doi.org/10.1158/1078-0432.CCR-08-0644 PMid:19088037

66. Chinnaiyan P, Wang M, Rojiani AM, et al. The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the radiation therapy oncology group. Radiation Oncology. 2008; 3(1):32–40. https://doi.org/10.1186/1748-717X-3-32 PMid:18817556 PMCid:PMC2563009

67. Burkhardt JK, Shin BJ, Boockvar JA. Neural Stem Cells and Glioma Stem-Like Cells Respond Differently to Chemotherapeutic Drugs: Selectivity at the Cellular Level. Neurosurgery. 2011; 68(6):21–22. https://doi.org/10.1227/01.neu.0000398212.65736.e1 PMid:21778947

68. Gong X, Schwartz PH, Linskey ME, et al. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology. 2011; 76(13):1126–1134. https://doi.org/10.1212/WNL.0b013e318212a89f PMid:21346220 PMCid:PMC3269770

How to Cite this Article

Semenova VM, Lisyany MI, Rosumenko VD, Egorova DM, Staino LP. The biological properties of cancer stem cells in malignant gliomas in tissue culture: a review. Cell and Organ Transplantology. 2015; 3(2):163-168. doi: 10.22494/COT.V3I2.12

Is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.